Răspunsul ţesuturilor periodontale la contraceptivele orale

 Response of periodontal tissues to oral contraceptives

First published: 04 decembrie 2020

Editorial Group: MEDICHUB MEDIA

DOI: 10.26416/Gine.30.4.2020.3946


In postmenopausal women, osteoporosis has a negative outcome on teeth stability. Based on estrogen receptors ERα and ERβ found in periodontal tissues, the replacement hormonal therapy by oral contraceptives improves the density of alveolar bone and teeth stability, but without regaining the previous height of alveolus. Some possible adverse effects, such as gingival bleeding, epulis, oral my­co­sis and aphtosis that cease in 1-5 weeks after stopping the therapy, can be also observed. However, there is still no agreement regarding the incidence of bacterial plaque, gingivitis, gingival bleeding index, pocket probing depth and periodontal destruction between healthy control and postmenopausal women using oral contraceptives.

oral contraceptives, gingival inflammation, alveolar bone resorption


La menopauză, osteoporoza afectează implantarea dinţilor. Graţie existenţei în ţesuturile parodontale a doi receptori es­tro­geni, ERα şi ERβ, tratamentul de substituţie hormonală prin contraceptive orale ameliorează densitatea osului alveolar şi stabilitatea dinţilor, dar nu asigură şi refacerea înălţimii pe­re­ţilor alveolei. Pot apărea însă şi efecte adverse, precum he­mo­ragii gingivale, epulis, micoze orale sau afte care cedează însă la 1-5 săptămâni după încetarea tratamentului. Totuşi, nu există încă un consens privind incidenţa plăcii bacteriene, gin­gi­vitei, indicelui de sângerare gingivală, adâncimii pun­gi­lor gingivale şi a gradului de distrucţie parodontală între fe­mei­le private de tratament hormonal şi cele care folosesc con­tra­cep­ti­vele orale.


The periodontal ligament is a non-mineralized type of connective tissue consisting in a heterogeneous mes­senchymal cell population, mainly fibroblastic and os­teo­genic or cementogenic, and attachment fibers with high content in collagen that links two distinct mine­ra­lized connective tissues, the root cementum and the al­veo­lus bone(1).

The initial inflammation of periodontal tissues, termed plaque-induced gingivitis, begins at the gingival mar­gin and modifies the local clinical appearance by chan­ging the gingival contour and color, increasing gin­gi­val exudates and producing bleeding on probing the gingival sulcus(2).

Without on time and appropriate treatment, the periodontal tissues inflammation progresses, and its more advanced stage is represented by chronic perio­dontitis. Along with worsening of the initial signs and symptoms of the initial inflammation, loss of clinical attachment and alveolar bone, enlargement or recession of gingiva, tooth mobility and drifting are the chief added expressions of the disease(3). Nevertheless, serum estradiol downregulates IL-1b release in gingival tissue, offering to menopausal and postmenopausal women a clinical improvement of gingival status(4).

Systemic bone in osteoporosis is also compromising the tooth stability, and the local alveolar bone loss might be a sign of advanced periodontal disease(5). Un­for­tunately, though the estrogen replacement therapy de­creases the alveolar bone porosity and strengthens the periodontal attachment, the bone socket height of af­fected teeth is not increased(6).

An extended study of postmenopausal osteoporotic women affected by chronic marginal periodontitis who followed an estrogen replacement therapy proved a lower incidence of deleterious effects of disease and lower costs of subsequent dental treatments than those hormonal untreated women(7). Moreover, the periodontally involved postmenopausal women receiving estrogen replacement therapy preserved more teeth than men or non-estrogen treated women of the same age(8).

Oral contraceptives

Contraceptives are estrogen and progesterone ges­ta­tio­nal hormones synthesized to diminish the pro­ba­bi­lity of ovulation(9). In regard to periodontal tis­sues, com­mon­ly, the clinical outcomes of hormonal con­tra­cep­tives intake, though lower in intensity, are similar to those found in pregnancy, such as enhanced gingival in­flam­mation and higher rate of exudates secretion in gin­gival sulcus(10).

During pregnancy, there occur obvious clinical and his­to­lo­gical changes in oral mucosa, particularly in gingi­val and periodontal tissues(11). The local effects of using oral contraceptives, emerging from major systemic disadvantages of these drugs, are gingival inflammation and loss of tooth attachment. The additional altered fibrinolytic activity is another deleterious outcome that has to be considered when surgical treatments are needed(12).

However, since the early 70s, in dental literature there have been mentioned numerous types of oral mu­co­sa lesions provoked by oral contraceptives, such as he­­mor­­rha­gic gingivitis, oral mycosis (Candida albicans), epu­lis, aphtosis, allergic erythema of the palate, and fa­­cial paralysis due to thrombosis of the facial artery that fortunately regressed in 1-5 weeks after stopping the medication(13).

As compared to formerly used oral contraceptives pills, which had a higher dosage of female sex hormones (20-50 mg estrogen/0.15-4 mg progesterone), the current formulations are delivered in lower daily amount of estrogen (0.05 mg) and progestins (1.5 mg)(14).

However, even in normal dose, progesterone-con­tai­ning contraceptives may trigger a higher secretion of gingival exudates and volumetric augmentation of gin­gi­val papillae since the proinflammatory cytokines and local metabolic breakdown produces released from oral bio­films induce an exaggerated response of human body. When overdosing, the clinical appearance in pregnant women are dominated by gingival erithema, bleeding, gingival hyperplasia, and pregnancy epulis(14,15).

In women using oral contraceptives, the volume of salivary secretion of major salivary glands is increased, but it was noted a decrease of sialic acid, salivary proteins, hexosaminefucose and full amount of electrolytes(14).

Though the clinical studies confirm that the gingival inflammation becomes more intense in women when using oral contraceptives, by comparing with healthy control women, there is still no agreement concerning the differences in plaque, gingivitis, gingival bleeding indexes, periodontal destruction, and pocket probing depth. There are also under debate the outcomes of currently combined contraceptives, depending on total duration of their intake(14).

Effects of female sex hormones
on periodontal tissues

Estrogens influence the periodontal tissues through various pathways:

  • the involvement in gingival fibroblasts proliferation, synthesis and maturation of local connective tissue;

  • increasing the degree of inflammation in gingival tis­sue, irrespective of bacterial biofilms presence;

  • stimulation of neutrophils phagocytosis;

  • slow down delivering of leukocytes from bone marrow;

  • suppressing proinflammatory cytokines secretion in bone marrow cells and T-cell mediated inflammation;

  • increasing the amount of acid mucopolysaccharide in oral mucosa;

  • declining the defense capability of oral epithelium by dropping the keratinization and augmenting the glycogen content(14).

Modalities of progesterone influence on the pe­rio­dontal tissues:

  • suppressing the proliferation of gingival fibroblasts and subsequent collagen and non-collagenous protein synthesis resulting in a slow down of repair and main­tenance potential of gingival collagen;

  • enhancing the prostaglandins secretion, vasodilatation, vascular permeability simultaneously with slowing down the antiinflammatory effect of glucocorticoids;

  • increasing the volume of gingival crevicular fluid and the amount of polymorphonuclear neutrophils and prostaglandin E2 coming out in gingival exudates(14).

Receptors of sex hormones
in periodontal tissues

Periodontal tissues are chiefly perceptive to changes in hormonal balance of female sex hormones. While inflamed, the gingival tissue, due to its ability of metabolizing the steroid hormones, is increasing the release of active breakdown products of testosterone and estrogens, excepting the progesterone whose final metabolites are inactive(16).

The female sex hormones act as a ligand for estrogen receptors that are characterized by tissue specific distribution(1). Estrogen (ER) and progesterone (PR) receptors were identified in human gingiva by bio­che­mical technique, but their binding sites could not be located. No difference was observed regarding the num­ber of binding sites between diseased gingival tissues and controls, though in phenytoin gingival hyperplasia their amount was higher compared to inflamed or heal­thy gingiva(17).

The estrogen receptors are transcription factors broad­ly expressed in different tissues as two subtypes, ERa and ERb(18). The cells of periodontal ligament have bin­ding sites for endogenous 17b-oestradiol, which binds to both aforementioned receptors, based on its high affinity for ERa and ERb proteins(19).

In addition to bone and lipid metabolism, the endothelial nitric oxide synthase activity is kept up by ERa expression. However, the data from literature regarding the ability of human periodontal cells to express specific mRNA for ERa receptors are still controversial(3), and the reason for their non-detection seems to be rather methodological(16).

The first report proving the ERb existence in pe­ri­­odon­tal ligament cells suggested that the gene ex­pres­sion relies mostly through ERb, as no obvious im­mu­no­reactivity for ERa was identified in cellular nuclei. Never­theless, no difference was noticed bet­ween males and females(18). Though earlier there were de­mon­strated both receptors ERa and ERb in the periodontal ligament cells by polymerase chain reaction, it seems that ERb is of major importance in mediating the gene transcription(18,20).

Periodontal ligament cells are stimulated by estro­gens in osteogenic activity through ERb, resulting in pro­li­feration, osteoblastic differentiation, collagen synthesis, and configuration of mineralized nodules. Not of less importance is the upregulation of key molecules such as alkaline phosphatase and osteocalcin or the ERb contribution in expressing the periostin, which is highly involved in preserving the anatomic integrity of periodontal tissue when the tooth is exposed during chewing to occlusal overload(1)

In addition to classically accepted ERa and ERb sig­naling(21), later on it was also reported a mitochondrial ERb, which induces in human periodontal ligament cells the slowdown of cytochrome c oxidase subunit I ex­pression, a mitochondrial enzyme engaged in oxi­da­tive phosphorylation(19). The mitochondrial gene trans­cription may be regulated by estrogen because the mitochondrial genome proved to be equipped with base-pair sequences belonging to the estrogen response ele­ments which bind both receptors ERa and ERb(1,22).

Though accepted that estrogens regulate ATP pro­duc­tion in mitochondria, the ERs subtype receptors in periodontal ligament cells are still not accurately proved. Moreover, unlike the periodontal tissue, in blood ves­sels estrogens enhance cytochrome c oxidase subunit I ex­pres­sion. An explanation might be the different cell types, such as endothelial and vascular smooth muscle which express both ERs receptors, ERa and ERb, as compared to periodontal ligament cells, expressing chiefly ERb(19).

The reduced energy release in periodontal ligament cells due to estrogen effect on cytochrome c oxidase subunit I expression downgrades the normal activity of cells, resulting in lower cell proliferation and collagen synthesis until another compensatory metabolic pathway under hypoxic conditions would be triggered(19).

There is a buildup of data advocating the presence of estrogen receptors in gingival tissue and fibroblasts, which are either spread out in lamina propria, or located in periodontal ligament. Moreover, these receptors were also found in periosteal fibroblasts and osteoblasts(14).

Looking for the presence of mRNAs corresponding to estrogen and androgen receptor expression by using the reverse-transcribed polymerase chain reaction, the androgen expression in human gingival and periodontal tissue and in corresponding fibroblasts was readily detected, unlike the transcripts for estrogen receptors that were not identified(23).

As DES (diethylstilbesterol) and DHT (dihy­dro­tes­to­sterone) do not modify the activity of the androgen receptor gene and do not induce the expression of the mRNA estrogen receptor in fibroblast, it was thought that the gingival tissue cannot respond directly to female sex hormones, but are sensitive to anabolic effects of androgens(23).

In postmenopausal women and in a 19-year-old woman, estrogen receptor mRNA were detected in oral mucosa, major salivary glands (parotid and sub­man­di­bular glands) and minor salivary glands (labial glands), proving the biological role of estrogens in oral cavity tissues(24).

Oral microflora – contraceptives interplay

Depending on microorganisms density inside the biofilms, the crosstalk between bacterial cells relies on a molecular signaling pathway, termed quorum sensing, which is in charge with gene expression of biofilm population. Moreover, these quorum sensing molecules proved to regulate the immune response of the host(25).

The basic task of this pathway is to coordinate bac­te­rial functions such as virulence, motility and ability for biofilm formation, and its efficiency is based upon three major classes of signaling molecules, known as au­to­in­ducers, as follows: Al-1, corresponding to Gram-ne­­ga­tive bacteria; Al-2, for both Gram-positive and Gram-negative bacteria; and Al-3, which is specific to E. coli and Salmonella(25).

The autoinducers are involved in cell migration, apoptosis and epithelial homeostasis, including the adhesion between gingival keratinocytes. It was also observed that Al-1 inducers may disrupt the epithelial barrier of the gingiva(25).

Some Prevotella species – such as P. intermedia, P. nigrescens, P. aurantiaca and P. pallens – proved to utilize estrogen and progesterone during pregnancy. Mainly P. intermedia and P. nigrescens are found in gingival inflammation and pregnancy gingivitis, as compared to P. pallens, which is mirroring the status of periodontal health(25).

P. intermedia and P. nigrescens augment the gingival keratinocytes production of IL-6 and IL-8 cytokines. Some Prevotella species are also in charge with cytokines IL-1 and IL-23 expression by activating TLR-2. However, Prevotella species may trigger the IL-6, IL-8 and CCL20 chemokine release from gingival epithelium, promoting the defensive immune response, as well as the PMN mi­gra­tion to the inflamed periodontal tissues(25).

Particularly P. intermedia is a recognized perio­don­to­pathogen positively correlated with increased amounts of estradiol and progesterone. However, 17b-estradiol slows down the TNF-a and IL-1b expression in gingival keratinocytes, as well as the release of TNF-a and IL-8 by ERb receptor(25).

Periodontopathogenic species of Prevotella intermedia were found in plaque samples of 22 out of 29 healthy women aged between 20 and 32 years old, before starting the medication with contraceptives containing 0.02 mg ethinyl estradiol and 0.15 mg desogestrel, respectively 0.03 mg ethinyl estradiol and 2 mg dienogest. After 10 day of contraceptive treatment, only a small variation of microbial content was found related to pretreatment status(26).

Some years ago, a novel procedure termed biotrans­for­mation was introduced in the pharmaceutical field to obtain drugs and chemicals. According to this technique, it was found that Cephalosporium aphidicola and Cunningshamella elegans fungi could metabolize oral contraceptives such as ethisterone (17a-ethynyl-17b-hydrozyandrost-4-en-3-one), a widely used synthetic steroid, having androgenic activity(27).

The biotransformation of ethisterone with Cu­n­ning­sha­mella blackesleeana ATCC 8688a re­sul­ted into two metabolites, 17a-ethynyl-6b,15b-trihydrozyandrost-4-en-3-one and 17a-ethy­nyl-7b,15b,17b-tri­hy­dro­zyandrost-4-en-3-one. Used in a biotransformation study, another fungus, Asper­gillus niger ATCC 1015, resulted in obtaining both a known metabolite, 17a-ethynyl-11a,17b-dihy­dro­zy­an­drost-4-en-3-one, and a new metabolite, 17a-ethynyl-6a,15b,17b-dihydrozyandrost-4-en-3-one. However, all these four metabolites must be assessed for their con­­tra­­cep­tive activity(28).


The periodontally involved postmenopausal women receiving estrogen replacement therapy seem to preserve more teeth than men or non-estrogen treated women of the same age, by proving a lower incidence of deleterious effects of periodontal disease, decreased severity of periodontal disease, and lower costs of subsequent dental treatments(29-31). Though the oral contraceptives increase alveolar bone density and strengthen the pe­rio­dontal attachment, they have no proved outcome on reconstructing the previous height of tooth alveo­lus. Also, the side effects of oral contraceptives in post­me­no­pausal women must be carefully monitored, knowing the risks associated with this therapy: coronary heart disease, thromboembolic stroke, breast and endometrial cancer(32)

Conflict of interests: The authors declare no conflict of interests.


  1. Mamalis A, Markopoulou C, Lagou A, Vrotsos I. Oestrogen regulates proliferation, osteoblastic differentiation, collagen synthesis and periostin gene expression in human periodontal ligament cells through oestrogen receptor beta. Arch Oral Biol. 2011;56:446-55.

  2. Claffey N. Plaque induced gingival disease. In: Lindhe J, Karring T, Lang N.P, eds, Clinical periodontology and implant dentistry, 4th ed, Blackwell-Munksgaard, Oxford. 2003:198-208.

  3. Kinane DF, Lindhe J. Chronic periodontitis. In: Lindhe J, Karring T, Lang NP, eds, Clinical periodontology and implant dentistry, 4th ed, Blackwell-Munksgaard, Oxford. 2003;209-15.

  4. Reinhardt RA, Payne JB, Maze C, Babbitt M, Nummikoski PV, Dunning D. Gingival fluid IL-1 beta in postmenopausal females on supportive periodontal therapy. 

  5. J Clin Periodontol. 1998;25:1029-35.

  6. Krall EA, Dawson-Hughes B, Papas A, Garcia RI. Tooth loss and skeletal bone density in healthy postmenopausal women. Osteoporosis. 1994;4:104-9.

  7. Taguchi A, Sanada M, Suei Y, et al. Effect of estrogen use on tooth retention, oral bone height, and oral bone porosity in Japanese postmenopausal women. Menopause. 2004;11:556-62.

  8. Allen IE, Monroe M, Connelly J, Cintron R, Ross SD. Effect of postmenopausal hormone replacement therapy on dental outcomes: systematic review of the literature and pharmacoeconomic analysis. Manag Care Interface. 2000;13:93-9.

  9. Meisel P, Reifenberger J, Haase R, Nauck M, Brandt C, Kocher T. Women are periodontally healthier than men, but why don’t they have more teeth than men? Menopause. 2008;15:270-5.

  10. Palmer R, Soory M. Modifying factors: diabetes, puberty, pregnancy and the menopause and tobacco smoking. Lindhe J, Karring T, Lang NP, eds. Clinical periodontology and implant dentistry, 4th ed, Blackwell-Munksgaard, Oxford. 2003;179-97.

  11. Mariotti A. Sex steroid hormones and cell dynamics in the periodontium. Crit Rev Oral Biol Med. 1994;5(1):27-53.

  12. Kristen VK. Changes in the mouth mucosa during pregnancy and hormonal contraceptive treatment. Fotschr Med. 1976;94(2):52-4. 

  13. Kennon S, Tasch EG, Arm RN. Considerations in the management of patients taking oral contraceptives. J Am Dent Ass.1978;97(4):641-3.

  14. Cohen-Bursztein F. The effect of oral contraceptives on the mouth mucosa. Acta Stomatol Belg. 1974;71(1):119-24.

  15. Nandini DB, Deepak BS, Sanjeeta NG, Sumita B, Aparna Devi P, Premlata T. Oral contraceptives and oral health: an insight. IJMDS. 2016; 5(2):1297-303.

  16. Iliescu ALA, Perlea P, Mitran M, Mitran L, Iliescu MG, Gheorghiu IM. Gingival bleeding in pregnancy. 2015;3:16-8.

  17. Ojanotko-Harri A, Forssell H, Laine M, Hurttia H, Bläuer M, Tuohimaa P. Immunohistochemical detection of androgen receptors in human oral mucosa. Arch Oral Biol. 1992;37(6):511-4.

  18. Vittek J, Hernandez MR, Weak EJ, Rappaport SC, Southren AL. Specific estrogen receptors in human gingival. J Clin Endocrinol Metab. 1982;54(3):608-12.

  19. Jönsson D, Andresson G, Ekblad E, Liang M, Bratthall G, Nilsson BO. Immunocytochemical demonstration of estrogen receptor β in human periodontal ligament cells. Arch Oral Biol. 2004;49(1):85-8.

  20. Jönsson D, Nilsson J, Odenlund M, Bratthall G, Broman J, Ekblad E, Lydrup ML, Nilsson BO. Demonstration of mitochondrial oestrogen receptor β and oestrogen-induced attenuation of cytochrome c oxidase subunit I expression in human periodontal ligament cells. Arch Oral Biol. 2007;52(7):669-76.

  21. Morishita M, Shimazu A, Iwamoto Y. Analysis of oestrogen receptor mRNA by gene transcriptase-polymerase chain reaction in human periodontal ligament cells. Arch Oral Biol. 1999;44(9):781-3.

  22. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in estrogen action. Ann Rev Physiol. 2001;63:165-192.

  23. Chen JQ, Eshete M, Alworth WL, Yager JD. Binding of MCF-7 cell mithocondrial proteins and recombinant human estrogen receptors alpha and beta to human mithocondrial DNA estrogen response elements. J Cell Biochem. 2004;93(2):358-73.

  24. Parkar MH, Newman HN, Olsen I. Polymerase chain reaction analysis of oestrogen and androgen receptor expression in human gingival and periodontal tissue. Arch Oral Biol. 1996;41(10):979-83.

  25. Lelmola-Virtanen R, Salo T, Tolkkanen S, Pulkkinen J, Syrjänen S. Expression of estrogen receptor (ER) in oral mucosa and salivary glands. Maturitas. 2000;36(2):131-7.

  26. Fteita D, Könönen E, Gürsoy M, Ma X, Sintim HO, Gürsoy UK. Quorum sensing molecules regulates epithelial cytokine response and biofilm-related virulence of three Prevotella species. Anaerobe. 2018;54:128-35.

  27. Klinger G, Eick S, Klinger G, Pfister W, Oettel M. Influence of hormonal contraceptives on microbial flora of gingival sulcus. Contraception. 1998;57(6):381-4.

  28. Choudhary MI, Sultan S, Khan MTH, Rahman AU. Microbial transformation of 17α-ethynyl-, and 17α-ethynylsteroids, and thyrosinase inhibitory activity of transformed products. Steroids. 2005;70(12):798-802.

  29. Aziz A, Bano S, Wahab AT, Choudhary MI. Microbial transformation of oral contraceptive ethisterone by Aspergillus niger and Cunninghamella blakesleeana. Steroids. 2020;154:108467.

  30. Bhardwaj A, Bhardwaj SV. Effect of menopause on women’s periodontium. 

  31. J Midlife Health. 2012;3(1):5–9.

  32. Norderyd M, Grossi G, Machtei E, Zambon JJ, Hausmann E, Dunford RG, et al. Periodontal status of women taking postmenopausal estrogen supplementation. J Periodontol. 1993;64(10):957–62. 

  33. Zachariasen R. Oral manifestations of menopause. Compendium. 1993;14:1584–91. 

  34. Lobo AR. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13(4):220-31. 

Articole din ediţiile anterioare

GYNECOLOGY | Ediţia 1 27 / 2020

Tratamentul medical al endometriozei: este opţiunea medicului?

Ciprian Andrei  Coroleucă, Diana-Elena Comandașu, Cătălin Bogdan Coroleucă, Mihai Mitran, Prof. Dr. Elvira Brătilă

Introducere. Endometrioza este o patologie cronică be­nig­nă, iar managementul ei implică adoptarea unei stra­te­gii pe termen lung care include tr...

13 martie 2020